|
1
|
Ando N, Kato H, Igaki H, Shinoda M, Ozawa
S, Shimizu H, Nakamura T, Yabusaki H, Aoyama N, Kurita A, et al: A
randomized trial comparing postoperative adjuvant chemotherapy with
cisplatin and 5-fluorouracil versus preoperative chemotherapy for
localized advanced squamous cell carcinoma of the thoracic
esophagus (JCOG9907). Ann Surg Oncol. 19:68–74. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ishida K, Ando N, Yamamoto S, Ide H and
Shinoda M: Phase II study of cisplatin and 5-fluorouracil with
concurrent radiotherapy in advanced squamous cell carcinoma of the
esophagus: A Japan esophageal oncology group (JEOG)/Japan clinical
oncology group trial (JCOG9516). Jpn J Clin Oncol. 34:615–619.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kato H, Sato A, Fukuda H, Kagami Y,
Udagawa H, Togo A, Ando N, Tanaka O, Shinoda M, Yamana H and
Ishikura S: A phase II trial of chemoradiotherapy for stage I
esophageal squamous cell carcinoma: Japan clinical oncology group
study (JCOG9708). Jpn J Clin Oncol. 39:638–643. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Loprinzi CL and Dose AM: Studies on the
prevention of 5-fluorouracil-induced oral mucositis. NCI Monogr.
93–94. 1990.PubMed/NCBI
|
|
5
|
Miaskowski C: Oral complications of cancer
therapies. Management of mucositis during therapy. NCI Monogr.
95–98. 1990.PubMed/NCBI
|
|
6
|
De Conno F, Ripamonti C, Sbanotto A and
Ventafridda V: Oral complications in patients with advanced cancer.
J Palliat Care. 5:7–15. 1989.PubMed/NCBI
|
|
7
|
Nishimura N, Nakano K, Ueda K, Kodaira M,
Yamada S, Mishima Y, Yokoyama M, Terui Y, Takahashi S and Hatake K:
Prospective evaluation of incidence and severity of oral mucositis
induced by conventional chemotherapy in solid tumors and malignant
lymphomas. Support Care Cancer. 20:2053–2059. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sakamoto K, Oka M, Yoshino S, Hazama S,
Abe T, Okayama N and Hinoda Y: Relation between cytokine promoter
gene polymorphism and toxicity of 5-fluorouracil plus cisplatin
chemotherapy. Oncol Rep. 16:381–387. 2006.PubMed/NCBI
|
|
9
|
Wang L, Hirayasu K, Ishizawa M and
Kobayashi Y: Purification of genomic DNA from human whole blood by
isopropanol-fractionation with concentrated Nal and SDS. Nucleic
Acids Res. 22:1774–1775. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hamajima N, Saito T, Matsuo K, Kozaki K,
Takahashi T and Tajima K: Polymerase chain reaction with
confronting two-pair primers for polymorphism genotyping. Jpn J
Cancer Res. 91:865–868. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ye S, Dhillon S, Ke X, Collins AR and Day
IN: An efficient procedure for genotyping single nucleotide
polymorphisms. Nucleic Acids Res. 29:E88–E98. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Okayama N, Fujimura K, Nakamura J, Suehiro
Y, Hamanaka Y and Hinoda Y: Evaluation of a new efficient procedure
for single-nucleotide polymorphism genotyping: Tetra-primer
amplification refractory mutation system-polymerase chain reaction.
Clin Chem Lab Med. 42:13–16. 2004.PubMed/NCBI
|
|
13
|
Aggarwal BB, Kohr WJ, Hass PE, Moffat B,
Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV and
Harkins RN: Human tumor necrosis factor. Production, purification,
and characterization. J Biol Chem. 260:2345–2354. 1985.PubMed/NCBI
|
|
14
|
Logan RM, Gibson RJ, Sonis ST and Keefe
DM: Nuclear factor-kappaB (NF-kappaB) and cyclooxygenase-2 (COX-2)
expression in the oral mucosa following cancer chemotherapy. Oral
Oncol. 43:395–401. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xanthinaki A, Nicolatou-Galitis O,
Athanassiadou P, Gonidi M, Kouloulias V, Sotiropoulou-Lontou A,
Pissakas G, Kyprianou K, Kouvaris J and Patsouris E: Apoptotic and
inflammation markers in oral mucositis in head and neck cancer
patients receiving radiotherapy: Preliminary report. Support Care
Cancer. 16:1025–1033. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morales-Rojas T, Viera N, Morón-Medina A,
Alvarez CJ and Alvarez A: Proinflammatory cytokines during the
initial phase of oral mucositis in patients with acute
lymphoblastic leukaemia. Int J Paediatr Dent. 22:191–196. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Logan RM, Stringer AM, Bowen JM, Gibson
RJ, Sonis ST and Keefe DM: Serum levels of NFkappaB and
pro-inflammatory cytokines following administration of mucotoxic
drugs. Cancer Biol Ther. 7:1139–1145. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Logan RM, Stringer AM, Bowen JM, Gibson
RJ, Sonis ST and Keefe DM: Is the pathobiology of
chemotherapy-induced alimentary tract mucositis influenced by the
type of mucotoxic drug administered? Cancer Chemother Pharmacol.
63:239–251. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Curra M, Martins MA, Lauxen IS, Pellicioli
AC, Sant'Ana Filho M, Pavesi VC, Carrard VC and Martins MD: Effect
of topical chamomile on immunohistochemical levels of IL-1β and
TNF-α in 5-fluorouracil-induced oral mucositis in hamsters. Cancer
Chemother Pharmacol. 71:293–299. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mira JP, Cariou A, Grall F, Delclaux C,
Losser MR, Heshmati F, Cheval C, Monchi M, Teboul JL, Riché F, et
al: Association of TNF2, a TNF-alpha promoter polymorphism, with
septic shock susceptibility and mortality: A multicenter study.
JAMA. 282:561–568. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Tang GJ, Huang SL, Yien HW, Chen WS, Chi
CW, Wu CW, Lui WY, Chiu JH and Lee TY: Tumor necrosis factor gene
polymorphism and septic shock in surgical infection. Crit Care Med.
28:2733–2736. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
O'Keefe GE, Hybki DL and Munford RS: The
G-->A single nucleotide polymorphism at the 308 position in the
tumor necrosis factor-alpha promoter increases the risk for severe
sepsis after trauma. J Trauma. 52:816–825. 2002.
|
|
23
|
Brinkman BM, Zuijdeest D, Kaijzel EL,
Breedveld FC and Verweij CL: Relevance of the tumor necrosis factor
alpha (TNF alpha) 308 promoter polymorphism in TNF alpha gene
regulation. J Inflamm. 46:32–41. 1995.PubMed/NCBI
|
|
24
|
Nakada TA, Hirasawa H, Oda S, Shiga H,
Matsuda K, Nakamura M, Watanabe E, Abe R, Hatano M and Tokuhisa T:
Influence of toll-like receptor 4, CD14, tumor necrosis factor, and
interleukine-10 gene polymorphisms on clinical outcome in Japanese
critically ill patients. J Surg Res. 129:322–328. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cui G, Wang H, Li R, Zhang L, Li Z, Wang
Y, Hui R, Ding H and Wang DW: Polymorphism of tumor necrosis factor
alpha (TNF-alpha) gene promoter, circulating TNF-alpha level, and
cardiovascular risk factor for ischemic stroke. J
Neuroinflammation. 9:2352012.PubMed/NCBI
|
|
26
|
Higuchi T, Seki N, Kamizono S, Yamada A,
Kimura A, Kato H and Itoh K: Polymorphism of the 5′-flanking region
of the human tumor necrosis factor (TNF)-alpha gene in Japanese.
Tissue Antigens. 51:605–612. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Barasch A and Peterson DE: Risk factors
for ulcerative oral mucositis in cancer patients: Unanswered
questions. Oral Oncol. 39:91–100. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hensley ML, Hagerty KL, Kewalramani T,
Green DM, Meropol NJ, Wasserman TH, Cohen GI, Emami B, Gradishar
WJ, Mitchell RB, et al: American society of clinical oncology 2008
clinical practice guideline update: Use of chemotherapy and
radiation therapy protectants. J Clin Oncol. 27:127–145.
2009.PubMed/NCBI
|
|
29
|
Lalla RV, Bowen J, Barasch A, Elting L,
Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O,
Peterson DE, et al: MASCC/ISOO clinical practice guidelines for the
management of mucositis secondary to cancer therapy. Cancer.
120:1453–1461. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Peterson DE, Boers-Doets CB, Bensadoun RJ
and Herrstedt J: ESMO Guidelines Committe: Management of oral and
gastrointestinal mucosal injury: ESMO clinical practice guidelines
for diagnosis, treatment and follow-up. Ann Oncol. 26:Suppl 5.
v139–v151. 2015. View Article : Google Scholar : PubMed/NCBI
|
